A randomized controlled trial of a therapeutic relational agent for reducing substance misuse during the COVID-19 pandemic
| Autor: | Judith J. Prochaska, Dale Dagar Maglalang, Kenneth R Weingardt, Alison M. Darcy, Erin A. Vogel, Amy Chieng, Athena Robinson, Michael Baiocchi, Sarah Pajarito |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Artificial intelligence medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Substance-Related Disorders COVID-19 pandemic Toxicology Article law.invention Randomized controlled trial law mental disorders Relational conversational agent Pandemic medicine Humans Pharmacology (medical) Psychiatry Pandemics Depression (differential diagnoses) Pharmacology biology SARS-CoV-2 business.industry COVID-19 biology.organism_classification Mental health Psychiatry and Mental health Mental Health Mood Anxiety Female Cannabis medicine.symptom business |
| Zdroj: | Drug and Alcohol Dependence |
| ISSN: | 0376-8716 |
| DOI: | 10.1016/j.drugalcdep.2021.108986 |
| Popis: | Author(s): Prochaska, Judith J; Vogel, Erin A; Chieng, Amy; Baiocchi, Michael; Maglalang, Dale Dagar; Pajarito, Sarah; Weingardt, Kenneth R; Darcy, Alison; Robinson, Athena | Abstract: BackgroundThe COVID-19 pandemic disrupted access to treatment for substance use disorders (SUDs), while alcohol and cannabis retail sales increased. During the pandemic, we tested a tailored digital health solution, Woebot-SUDs (W-SUDs), for reducing substance misuse.MethodsIn a randomized controlled trial, we compared W-SUDs for 8 weeks to a waitlist control. U.S. adults (N = 180) who screened positive for substance misuse (CAGE-AIDg1) were enrolled June-August 2020. The primary outcome was the change in past-month substance use occasions from baseline to end-of-treatment (EOT). Study retention was 84%. General linear models tested group differences in baseline-to-EOT change scores, adjusting for baseline differences and attrition.ResultsAt baseline, the sample (age M = 40, SD = 12, 65% female, 68% non-Hispanic white) averaged 30.2 (SD = 18.6) substance occasions in the past month. Most (77%) reported alcohol problems, 28% cannabis, and 45% multiple substances; 46% reported moderate-to-severe depressive symptoms. Treatment participants averaged 920 in-app text messages (SD = 892, Median = 701); 96% of completed lessons were rated positively; and 88% would recommend W-SUDs. Relative to waitlist, W-SUDs participants significantly reduced past-month substance use occasions (M = -9.1, SE = 2.0 vs. M = -3.3, SE = 1.8; p = .039). Secondary substance use and mood outcomes did not change significantly by group; however, reductions in substance use occasions correlated significantly with increased confidence and fewer substance use problems, cravings, depression and anxiety symptoms, and pandemic-related mental health effects (p-valuel.05).ConclusionsW-SUDs was associated with significant reductions in substance use occasions. Reduction in substance use occasions was associated with better outcomes, including improved mental health. W-SUDs satisfaction was high. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect